Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 P/E Ratio

The latest P/E ratio for CYCCP is -0.22. That is below the Healthcare sector average of 26.36. Investors often review this figure alongside Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CYCCP currently prints -0.22 for P/E ratio, while the sector average sits near 26.36. That is roughly 100.8% below the sector mean. Large gaps often invite a closer look at Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's growth, margins, and balance sheet.

A P/E ratio of -0.22 for Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with CYCCP's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CYCCP's P/E ratio (-0.22), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.